Accordingly, the combination of plasmatic IGFBP2 and anti-IGFBP2 antibodies levels has already been tested in lung, glioma, and colorectal cancer patients and found to improve not only diagnostic efficacy of the test, but also its prognostic power. This evidence concerns the gene IGFBP2 and colorectal cancer.